Ryan Henning

Ryan Henning, Ph.D., currently serves as an Affiliate Scientist at Berkeley Lab, focusing on synthetic biology and genetic engineering to create a carbon-negative platform for biologic manufacturing using photosynthetic cyanobacteria and developing a biological platform for carbon capture. Previously, as a Principal Scientist at Applied Molecular Transport, Ryan led a pre-clinical pipeline program for a therapy targeting intestinal injury and established a pharmacodynamic marker for imaging-based studies. At BridgeBio, Ryan held dual roles, first as Director of Research and Development for Ferro Therapeutics, where a new oncology discovery group was formed, and as Co-Founder of Quartz Therapeutics, which developed an orally bioavailable small molecule degrader. Ryan's early career includes a postdoctoral position at the University of California, San Francisco, and a graduate program at Caltech, culminating in a Ph.D. in Chemistry. Ryan also completed a fellowship at the National Institutes of Health, focusing on cancer research.